LAB.MC Labiana Health S.A.
- Market cap
- EUR 43.7M
- P/E
- 14.7x
- P/B
- 8.68x
- ROE
- 50.5%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LAB.MC undervalued?
Graham numberLAB.MC trades 138.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Labiana Health S.A. fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (50.5%), above 20%.
ROA 1/1
Return on assets (4.5%) is above the industry median (3.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (921.5%) is above the industry median (78.1%).
Revenue Growth 1/2
Revenue grew 9.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (586.4%), above 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 1.2x against interest expense, below 5x.
PE vs Market 1/1
PE (14.7x) is below the market median (16.3x).
PE vs Industry 1/1
PE (14.7x) is below the industry median (17.6x).
PBV 0/1
Price to book (8.7x) is above the industry median (1.7x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 127.8, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Labiana Health S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Labiana Health S.A.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina La…
Full company profileLabiana Health S.A. financial statements
Labiana Health S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 57.8M | 57.0M | 57.8M | 58.5M | 66.3M | 75.2M |
| Gross Profit | 34.1M | 35.4M | 32.5M | 34.3M | 40.9M | 46.0M |
| Operating Income | 2.46M | 540K | -6.23M | -1.84M | 5.10M | 7.30M |
| EBITDA | - | - | -894K | 3.11M | 9.06M | 10.9M |
| Net Income | 1.07M | -1.78M | -8.94M | -4.42M | 253K | 2.57M |
| EPS | - | -0.25 | -1.25 | -0.61 | 0.04 | 0.36 |
| Balance Sheet | ||||||
| Total Assets | - | 68.4M | 60.8M | 59.1M | 52.0M | 57.5M |
| Total Liabilities | - | 56.8M | 53.0M | 55.7M | 49.4M | 52.8M |
| Shareholders' Equity | - | 11.6M | 7.74M | 3.58M | 2.87M | 5.08M |
| Cash & Short-term Investments | - | 3.28M | 2.54M | 2.96M | 6.74M | 5.91M |
| Cash Flow | ||||||
| Operating Cash Flow | - | 3.91M | 4.68M | -1.83M | 7.19M | 1.70M |
| Capital Expenditure | - | 4.77M | 5.45M | 2.85M | 3.05M | 4.44M |
| Free Cash Flow | - | -859K | -774K | -4.68M | 4.15M | -2.74M |
| Ratios | ||||||
| ROE | - | -15.3% | -115.5% | -123.5% | 8.8% | 50.5% |
| ROA | - | -2.6% | -14.7% | -7.5% | 0.5% | 4.5% |
| Net Profit Margin | 1.9% | -3.1% | -15.5% | -7.6% | 0.4% | 3.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Labiana Health S.A. dividends
Labiana Health S.A. has not paid dividends in the last 5 fiscal years.
Who owns Labiana Health S.A.
- Insiders 63.07%
- Institutions 9.76%
- Public & others 27.17%
- Shares outstanding 8.49M
- Free float 2.10M
Labiana Health S.A. company profile
- Company name
- Labiana Health S.A.
- Ticker
- LAB.MC
- ISIN
- ES0105638003
- Exchange
- Madrid Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 373
- Fiscal year end
- December
- Address
- Av. Europa, Pozuelo de Alarcón, Spain, 28023
- Phone
- 34 919 91 26 28
- Website
- labiana.com
About Labiana Health S.A.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, it offers contract development and manufacturing services. The company was founded in 1958 and is based in Pozuelo de Alarcón, Spain.
Labiana Health S.A. management
8- Mr. Manuel Ramos OrtegaPresident, CEO & Chairman
- Mr. Miquel Pujolriu GimenezCFO & Secretary of the Board
- Cristina Ramos RecoderDirector of Investor Relations
- Ivana NovoaHR Director
- Ms. Sandra Villagrasa ClementeExecutive Director
- Xavier Perez RamosManaging Director of Animal Division
- Dragoljub MilinkovicManaging Director of Zavod
- Suva KayaManaging Director of Zoleant